GRAND RAPIDS, Mich. — Paul Hudson is running for United States Congress representing Michigan's third district. He opposes incumbent Hillary Scholten. Hudson shared his campaign strategy and key ...

Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, 2025 outlook, drug pipeline, the company's dividend and buyback decision, his thoughts on the ...

(CBS DETROIT) — Democratic Congresswoman Hillary Scholten has fended off Republican attorney Paul Hudson in Michigan's 3rd Congressional District race, CBS News projects. "I set out to build a new ...

GRAND RAPIDS, Mich. — Incumbent Democrat U.S. Rep. Hillary Scholten faces Republican challenger Paul Hudson in the general election. Scholten was first elected to the House in 2022 and is running for ...

Sanofi shares fell after the drugmaker said Belen Garijo, the chief executive of Germany’s Merck KGaA, would succeed Paul Hudson as CEO after its board decided not to renew his mandate. The change at ...

[People] delegate AI to CDOs, and it's the biggest mistake you can make. At last year’s World Economic Forum gathering in Davos, Paul Hudson, CEO of French pharma giant Sanofi, made the case for AI ...

Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, drug pipeline outlook, the company's Dupixent drug, and more. Got a confidential news tip? We want to ...

Amid mounting concerns about the state of vaccine policy in the U.S., Sanofi's leadership is keeping a cool head while acknowledging that the company's immunizations sales are slated to decline again ...

GRAND RAPIDS, MI — Republicans rallied Wednesday evening in Grand Rapids, urging supporters to knock on doors and get out the vote as they seek to win key races and put the GOP in control of the state ...

Washington — The campaign to reelect Democratic U.S. Rep. Hillary Scholten on Wednesday launched its second ad since she cruised to victory in her party's primary last month. The 30-second ad, titled ...

Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, Blueprint acquisition, strong demand for Dupixent, drug pipeline outlook, impact of tariffs, and more.